On Tuesday, Cancer Genetics CGIX will release its latest earnings report. Check out Benzinga's report to understand the earnings report's implications.
Earnings and Revenue
Wall Street analysts see Cancer Genetics reporting a loss of 16 cents per share on revenue of $8.3 million.
In the same quarter last year, Cancer Genetics announced an EPS loss of 16 cents on revenue of $6.6 million. Sales would be up 25.68 percent from the same quarter last year. Here's how the company's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q1 2018 | Q4 2017 | Q3 2017 | Q2 2017 |
| EPS Estimate | -0.13 | -0.11 | -0.12 | -0.15 |
| EPS Actual | -0.16 | -0.36 | -0.16 | -0.16 |
Stock Performance
Over the last 52-week period, shares are down 73.38 percent. Given that these returns are generally negative, long-term shareholders are probably down going into this earnings release. Over the past 90 days, analysts have not modified their estimates for EPS and revenues. The average rating by analysts on Cancer Genetics stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
Conference Call
Cancer Genetics' Q2 conference call is scheduled to begin at 8:30 a.m. ET and can be accessed here: http://public.viavid.com/player/index.php?id=130945
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
